论文部分内容阅读
目的:探讨东菱克栓酶大剂量冲击疗法对发病6小时～16小时脑梗塞病人的疗效,不良反应和安全性。方法:选择该时间段内病人35例为观察组,30例使用该药常规剂量为对照组,分别对两组治疗前、治疗开始后1周末和4周末的病人情况进行统计学对比分析。结果:两组间治疗前情况无差异,治疗开始后观察组神经缺损评分迅速减少,1周末和4周末较对照组均有明显差异,观察组总显效率显著优于对照组且进展性卒中发生率明显减少,梗塞后出血发生率两组无显著差异。结论:在发病6小时～16小时的脑梗塞病人中东(?)克栓酶大剂量冲击疗法疗效仍显著优于对照组,起效迅速,进展性卒中发生率明显减少,梗塞后出血无明显增加,无其它明显不良反应,安全性良好。
OBJECTIVE: To investigate the curative effect, side effects and safety of boll bolus high dose shock therapy on patients with cerebral infarction aged 6 hours to 16 hours. Methods: 35 patients in the time period were selected as the observation group and 30 patients were used as the control group. The patients in the two groups before treatment, 1 week after the start of treatment and 4 weeks after the start of treatment were statistically analyzed. Results: There was no difference between the two groups before treatment. After the treatment, the score of neurological deficit in the observation group decreased rapidly. There was a significant difference between the two groups at the end of the first week and the end of the fourth week. The total effective rate in the observation group was significantly better than that in the control group and the progressive stroke occurred Rate was significantly reduced, the incidence of post-infarction bleeding no significant difference between the two groups. Conclusion: Middle-East (?) Kexu enzyme dose-shock therapy is still significantly better than the control group in patients with cerebral infarction of 6 hours to 16 hours of onset, rapid onset, significantly reduced incidence of progressive stroke, no significant increase in post-infarction bleeding , No other obvious adverse reactions, good safety.